Autoimmune diseases (AIDs) affect about 5% of the population. As systemic therapies are rarely curative for patients with severe, life-threatening forms of AIDs, there is a need for better treatment. During the past 15 years, HSCT has been developed as a potential clinical therapy. Durable...